Pub Date : 2024-02-22DOI: 10.14412/2074-2711-2024-1-102-113
O. Gromova, I. Torshin, M. V. Filimonova, D. E. Frolova
In periodicals, vitamins and vitamin-mineral complexes (VMCs) are “accused” of having allegedly carcinogenic effects. The results of a systematic review of the literature on B vitamins presented in this paper clearly show that vitamins have at least no influence on tumour risk. When analysing experimental and clinical data on this topic, particular attention should be paid to the dosage of vitamins in monotherapy and when used as part of a VMCs.
在期刊上，维生素和维生素矿物质复合物（VMCs）被 "指控 "具有所谓的致癌作用。本文对有关 B 族维生素的文献进行系统回顾的结果清楚地表明，维生素至少对肿瘤风险没有影响。在分析有关这一主题的实验和临床数据时，应特别注意维生素在单一疗法中的用量以及作为维生素复合制剂的一部分使用时的用量。
{"title":"On the antitumour effects of B vitamins","authors":"O. Gromova, I. Torshin, M. V. Filimonova, D. E. Frolova","doi":"10.14412/2074-2711-2024-1-102-113","DOIUrl":"https://doi.org/10.14412/2074-2711-2024-1-102-113","url":null,"abstract":"In periodicals, vitamins and vitamin-mineral complexes (VMCs) are “accused” of having allegedly carcinogenic effects. The results of a systematic review of the literature on B vitamins presented in this paper clearly show that vitamins have at least no influence on tumour risk. When analysing experimental and clinical data on this topic, particular attention should be paid to the dosage of vitamins in monotherapy and when used as part of a VMCs.","PeriodicalId":19252,"journal":{"name":"Neurology, neuropsychiatry, Psychosomatics","volume":"29 17","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140442165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-22DOI: 10.14412/2074-2711-2024-1-75-81
V. V. Goldobin, E. Klocheva, A. Dil, V. I. Golovkin, I. V. Chistova
Autoimmune encephalitis with antibodies against NMDA receptor (anti-NMDA encephalitis) is a relatively newly described disease that occupies a leading position among encephalitis of various etiologies. The article presents diagnostic criteria for this disease and describes a case of an atypical course of confirmed anti-NMDA encephalitis. The peculiarities of this observation are the relatively mild course of the disease with the development of generalized seizures, mental and cognitive disorders at the onset of the disease. The difficulties in diagnosis and possible pathogenetic aspects of the disease are discussed.
{"title":"Clinical case of an atypical course of autoimmune anti-NMDA encephalitis","authors":"V. V. Goldobin, E. Klocheva, A. Dil, V. I. Golovkin, I. V. Chistova","doi":"10.14412/2074-2711-2024-1-75-81","DOIUrl":"https://doi.org/10.14412/2074-2711-2024-1-75-81","url":null,"abstract":"Autoimmune encephalitis with antibodies against NMDA receptor (anti-NMDA encephalitis) is a relatively newly described disease that occupies a leading position among encephalitis of various etiologies. The article presents diagnostic criteria for this disease and describes a case of an atypical course of confirmed anti-NMDA encephalitis. The peculiarities of this observation are the relatively mild course of the disease with the development of generalized seizures, mental and cognitive disorders at the onset of the disease. The difficulties in diagnosis and possible pathogenetic aspects of the disease are discussed.","PeriodicalId":19252,"journal":{"name":"Neurology, neuropsychiatry, Psychosomatics","volume":"76 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140439921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-22DOI: 10.14412/2074-2711-2024-1-87-93
M. A. Kantova, E. M. Ivanova, Yuriy Mikadze
A review of studies analysing the process of humour perception under normal conditions and its disturbances in brain damage is presented. The perception of humour is considered to be a multicomponent mental activity that occurs through a series of cognitive and affective processes characterized by a specific brain organization. The results of studies on the perception of humour in healthy people and in patients with brain damage are largely inconsistent: neuroimaging studies confirm the important role of structures of both hemispheres of the brain, while clinical data indicate a significant contribution of structures of the right hemisphere to the perception of humour. Studies on humour perception in healthy individuals and clinical studies have found no differences between the neuronal correlates of verbal and non-verbal humour perception. A neuropsychological approach to the study of the structure of the process of humour perception may be important for diagnosis of affective and cognitive disorders in patients with brain damage, as difficulties in the perception of humour may reflect disturbances of the most subtle aspects of the functioning and interaction of cognitive and emotional-personal processes.
{"title":"Neuropsychological assessment of the morphofunctional organization of humour perception processes","authors":"M. A. Kantova, E. M. Ivanova, Yuriy Mikadze","doi":"10.14412/2074-2711-2024-1-87-93","DOIUrl":"https://doi.org/10.14412/2074-2711-2024-1-87-93","url":null,"abstract":"A review of studies analysing the process of humour perception under normal conditions and its disturbances in brain damage is presented. The perception of humour is considered to be a multicomponent mental activity that occurs through a series of cognitive and affective processes characterized by a specific brain organization. The results of studies on the perception of humour in healthy people and in patients with brain damage are largely inconsistent: neuroimaging studies confirm the important role of structures of both hemispheres of the brain, while clinical data indicate a significant contribution of structures of the right hemisphere to the perception of humour. Studies on humour perception in healthy individuals and clinical studies have found no differences between the neuronal correlates of verbal and non-verbal humour perception. A neuropsychological approach to the study of the structure of the process of humour perception may be important for diagnosis of affective and cognitive disorders in patients with brain damage, as difficulties in the perception of humour may reflect disturbances of the most subtle aspects of the functioning and interaction of cognitive and emotional-personal processes.","PeriodicalId":19252,"journal":{"name":"Neurology, neuropsychiatry, Psychosomatics","volume":"67 9","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140439967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-22DOI: 10.14412/2074-2711-2024-1-94-101
A. L. Kurenkov, B. Bursagova, A. R. Artemenko
Pain in cerebral palsy (CP) occurs in 30–60% of cases. Pain associated with spasticity (PAS) is one of the most common causes of pain syndrome in cerebral palsy, which is often associated with impairment of the child’s daily life. Recently, more studies have been published on the use of botulinum toxin type A preparations to control PAS. The review article presents the results of a special pooled analysis of data on the analgesic effect of the drug Xeomin (incobotulinumtoxin A) in the treatment of PAS based on data from three phase III multicentre prospective comparative studies in children and adolescents with spastic forms of cerebral palsy. To evaluate PAS and the effect of incobotulinumtoxin A on it, a special questionnaire (Questionnaire on Pain caused by Spasticity, QPS) was used in these studies. The QPS reflects the child's pain associated with spasticity, which can be observed at rest and during various activities of the child.It was found that the children included in these studies reported the presence of PAS in more than 80% of cases with lower limb spasticity and in almost 70% of cases with upper limb spasticity. Parents or caregivers of these children observed an even higher prevalence of PAS. The use of incobotulinumtoxin A showed not only a pronounced antispastic effect, but also a significant reduction in the frequency and intensity of PAS in children and adolescents with cerebral palsy during normal daily activities, and during strenuous activities such as physical exercise and rehabilitation treatment. With repeated injection cycles of incobotulinumtoxin A, PAS continued to decrease, ensuring a reduction in pain even when physical activity became more difficult. Nowadays, injections with incobotulinumtoxin A can be considered as a routine therapeutic approach for the treatment of spasticity and increased muscle tone, but it is certainly an innovative method for effective pain reduction in cerebral palsy patients with lower and upper limb spasticity accompanied by PAS.
30-60% 的脑瘫（CP）患者会出现疼痛。与痉挛相关的疼痛（PAS）是导致脑瘫疼痛综合征的最常见原因之一，通常会影响患儿的日常生活。最近，关于使用 A 型肉毒毒素制剂控制 PAS 的研究越来越多。这篇综述文章基于三项针对痉挛型脑瘫儿童和青少年的III期多中心前瞻性对比研究数据，对药物Xeomin（incobotulinumtoxin A）治疗PAS的镇痛效果进行了专门的汇总分析。为了评估痉挛性肢体麻痹及其对伊可菌素 A 的影响，这些研究采用了一种特殊的调查问卷（痉挛性疼痛问卷，QPS）。QPS反映的是儿童在休息和各种活动时与痉挛相关的疼痛。研究发现，在这些研究中，80%以上的下肢痉挛患儿和近70%的上肢痉挛患儿报告存在PAS。据这些儿童的父母或看护人观察，PAS 的发病率甚至更高。使用伊科保妥适 A 不仅具有明显的抗痉挛效果，还能显著降低脑瘫儿童和青少年在正常日常活动以及体育锻炼和康复治疗等剧烈活动中出现痉挛性抽搐的频率和强度。通过反复注射伊科菌素 A，PAS 持续下降，即使在体力活动变得更加困难时，也能确保疼痛减轻。如今，注射伊科保妥适 A 可被视为治疗痉挛和肌张力增高的常规治疗方法，但对于伴有 PAS 的上下肢痉挛的脑瘫患者来说，这无疑是一种有效减轻疼痛的创新方法。
{"title":"Assessment of spasticity-related pain in cerebral palsy and the efficacy of its treatment with incobotulinumtoxin A (literature review)","authors":"A. L. Kurenkov, B. Bursagova, A. R. Artemenko","doi":"10.14412/2074-2711-2024-1-94-101","DOIUrl":"https://doi.org/10.14412/2074-2711-2024-1-94-101","url":null,"abstract":"Pain in cerebral palsy (CP) occurs in 30–60% of cases. Pain associated with spasticity (PAS) is one of the most common causes of pain syndrome in cerebral palsy, which is often associated with impairment of the child’s daily life. Recently, more studies have been published on the use of botulinum toxin type A preparations to control PAS. The review article presents the results of a special pooled analysis of data on the analgesic effect of the drug Xeomin (incobotulinumtoxin A) in the treatment of PAS based on data from three phase III multicentre prospective comparative studies in children and adolescents with spastic forms of cerebral palsy. To evaluate PAS and the effect of incobotulinumtoxin A on it, a special questionnaire (Questionnaire on Pain caused by Spasticity, QPS) was used in these studies. The QPS reflects the child's pain associated with spasticity, which can be observed at rest and during various activities of the child.It was found that the children included in these studies reported the presence of PAS in more than 80% of cases with lower limb spasticity and in almost 70% of cases with upper limb spasticity. Parents or caregivers of these children observed an even higher prevalence of PAS. The use of incobotulinumtoxin A showed not only a pronounced antispastic effect, but also a significant reduction in the frequency and intensity of PAS in children and adolescents with cerebral palsy during normal daily activities, and during strenuous activities such as physical exercise and rehabilitation treatment. With repeated injection cycles of incobotulinumtoxin A, PAS continued to decrease, ensuring a reduction in pain even when physical activity became more difficult. Nowadays, injections with incobotulinumtoxin A can be considered as a routine therapeutic approach for the treatment of spasticity and increased muscle tone, but it is certainly an innovative method for effective pain reduction in cerebral palsy patients with lower and upper limb spasticity accompanied by PAS.","PeriodicalId":19252,"journal":{"name":"Neurology, neuropsychiatry, Psychosomatics","volume":"32 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140442138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-22DOI: 10.14412/2074-2711-2024-1-82-86
N. Shamalov, L. V. Klimov, M. Soldatov, T. V. Kiseleva, V. N. Shamalova, N. A. Marskaya, O. Lyang
The incidence of neurological complications in COVID-19 can reach 8–10% of all cases of new coronavirus infection; acute cerebrovascular accidents (ACA) dominate in their structure, which cause significant social and economic costs due to the high mortality and disability rates in this group of patients. The main pathophysiological mechanism leading to the development of ischemic cerebrovascular accidents (ischemic stroke, transient ischemic attack) is the phenomenon of hypercoagulation, which, together with the systemic inflammatory response to the viral infection, leads to the formation of macro- and microthrombi and the development of ischemic disorders of cerebral circulation. The ischemic stroke associated with COVID-19 is characterized by the onset at a younger age, the predominance of cryptogenic and cardioembolic pathogenetic variants, a more frequent occlusion of large cerebral vessels and thus a more pronounced clinical picture of the disease. The reserves for reducing mortality and disability in patients with cerebrovascular disease, especially stroke, during the spread of COVID-19 lie both in the prevention, treatment and rehabilitation of COVID-19 in patients at high risk of developing cardiovascular diseases and in ensuring specialized medical care for this category of patients.
{"title":"Acute cerebrovascular accidents in patients with new coronavirus infection COVID-19","authors":"N. Shamalov, L. V. Klimov, M. Soldatov, T. V. Kiseleva, V. N. Shamalova, N. A. Marskaya, O. Lyang","doi":"10.14412/2074-2711-2024-1-82-86","DOIUrl":"https://doi.org/10.14412/2074-2711-2024-1-82-86","url":null,"abstract":"The incidence of neurological complications in COVID-19 can reach 8–10% of all cases of new coronavirus infection; acute cerebrovascular accidents (ACA) dominate in their structure, which cause significant social and economic costs due to the high mortality and disability rates in this group of patients. The main pathophysiological mechanism leading to the development of ischemic cerebrovascular accidents (ischemic stroke, transient ischemic attack) is the phenomenon of hypercoagulation, which, together with the systemic inflammatory response to the viral infection, leads to the formation of macro- and microthrombi and the development of ischemic disorders of cerebral circulation. The ischemic stroke associated with COVID-19 is characterized by the onset at a younger age, the predominance of cryptogenic and cardioembolic pathogenetic variants, a more frequent occlusion of large cerebral vessels and thus a more pronounced clinical picture of the disease. The reserves for reducing mortality and disability in patients with cerebrovascular disease, especially stroke, during the spread of COVID-19 lie both in the prevention, treatment and rehabilitation of COVID-19 in patients at high risk of developing cardiovascular diseases and in ensuring specialized medical care for this category of patients.","PeriodicalId":19252,"journal":{"name":"Neurology, neuropsychiatry, Psychosomatics","volume":"37 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140439469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-22DOI: 10.14412/2074-2711-2024-1-114-121
G. E. Ivanova, N. L. Kunelskaya, V. A. Parfenov, M. V. Zamergrad, O. A. Melnikov, A. L. Guseva, O. V. Zaitseva, A. A. Shmonin, E. V. Baybakova, M. N. Maltseva
Experts discussed the problem of comprehensive medical treatment of vertigo through vestibular rehabilitation. Peripheral vestibular vertigo is most commonly caused by benign paroxysmal positional vertigo, Meniere's disease and vestibular neuronitis, while central vestibular vertigo is caused by vestibular migraine and stroke. Vestibular rehabilitation is one of the most effective areas of treatment for patients with various disorders of the vestibular system characterized by chronic dizziness. Vestibular rehabilitation improves patients' walking and stability and can lead to an improvement in patients' daily activities and quality of life. Currently, in our country medical rehabilitation centres are being established where patients with various causes of vestibular vertigo can receive complex therapy, including vestibular rehabilitation. The Expert Council recommends the comprehensive personalised use of vestibular rehabilitation in the complex treatment of various diseases manifested by dizziness. An educational program is needed for neurologists, ENT specialists and rehabilitation specialists in treatment of patients with different types of vestibular dizziness.
{"title":"Vestibular rehabilitation in complex therapy of vestibular vertigo (consensus of experts)","authors":"G. E. Ivanova, N. L. Kunelskaya, V. A. Parfenov, M. V. Zamergrad, O. A. Melnikov, A. L. Guseva, O. V. Zaitseva, A. A. Shmonin, E. V. Baybakova, M. N. Maltseva","doi":"10.14412/2074-2711-2024-1-114-121","DOIUrl":"https://doi.org/10.14412/2074-2711-2024-1-114-121","url":null,"abstract":"Experts discussed the problem of comprehensive medical treatment of vertigo through vestibular rehabilitation. Peripheral vestibular vertigo is most commonly caused by benign paroxysmal positional vertigo, Meniere's disease and vestibular neuronitis, while central vestibular vertigo is caused by vestibular migraine and stroke. Vestibular rehabilitation is one of the most effective areas of treatment for patients with various disorders of the vestibular system characterized by chronic dizziness. Vestibular rehabilitation improves patients' walking and stability and can lead to an improvement in patients' daily activities and quality of life. Currently, in our country medical rehabilitation centres are being established where patients with various causes of vestibular vertigo can receive complex therapy, including vestibular rehabilitation. The Expert Council recommends the comprehensive personalised use of vestibular rehabilitation in the complex treatment of various diseases manifested by dizziness. An educational program is needed for neurologists, ENT specialists and rehabilitation specialists in treatment of patients with different types of vestibular dizziness.","PeriodicalId":19252,"journal":{"name":"Neurology, neuropsychiatry, Psychosomatics","volume":"26 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140441277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-21DOI: 10.14412/2074-2711-2024-1-65-70
G. Belskaya, A. V. Krasnikov, E. A. Kiryanova, M. E. Prokopovich, E. V. Sakharova, G. V. Makarov
Objective: to evaluate the efficacy and safety of fremanezumab in patients with chronic migraine (CM) in real-life clinical practice.Material and methods. In a 12-week, open-label, prospective study, 27 patients (21 women and 6 men, mean age 41±10 years) with CM were administered with fremanezumab 225 mg subcutaneously monthly or 675 mg once (quarterly). We assessed changes in migraine attack intensity using a visual analogue scale (VAS), a reduction in the number of headache days per month by 50% or more, the impact of headache on daily activities (HIT-6 scale), adverse events (AEs) and tolerability of fremanezumab.Results. The number of migraine days per month decreased by 50% or more in 52%, 63% and 70% of patients at weeks 4, 8 and 12, respectively. In 26% of patients, the number of days with headaches was reduced by 75% or more by the end of the study. On average, the number of days with migraine decreased by 11.6 per month, with monthly injections – by 12.6 per month (p<0.01). In patients who had negative experience with treatment with two or more groups of preventive therapies, the number of days with migraine was reduced by an average of 10.6 per month (p<0.01). The pain intensity according to VAS decreased from 9 to 5.7 points (p<0.001), the HIT-6 index decreased from 66 to 55 points (p<0.001). AEs occurred in 26% of cases, were transient and did not lead to discontinuation of treatment.Conclusion. The efficacy and safety of the use of fremanezumab in CM in real-world clinical practice has been demonstrated.
{"title":"Safety and efficacy of fremanezumab in real clinical practice in patients with chronic migraine","authors":"G. Belskaya, A. V. Krasnikov, E. A. Kiryanova, M. E. Prokopovich, E. V. Sakharova, G. V. Makarov","doi":"10.14412/2074-2711-2024-1-65-70","DOIUrl":"https://doi.org/10.14412/2074-2711-2024-1-65-70","url":null,"abstract":"Objective: to evaluate the efficacy and safety of fremanezumab in patients with chronic migraine (CM) in real-life clinical practice.Material and methods. In a 12-week, open-label, prospective study, 27 patients (21 women and 6 men, mean age 41±10 years) with CM were administered with fremanezumab 225 mg subcutaneously monthly or 675 mg once (quarterly). We assessed changes in migraine attack intensity using a visual analogue scale (VAS), a reduction in the number of headache days per month by 50% or more, the impact of headache on daily activities (HIT-6 scale), adverse events (AEs) and tolerability of fremanezumab.Results. The number of migraine days per month decreased by 50% or more in 52%, 63% and 70% of patients at weeks 4, 8 and 12, respectively. In 26% of patients, the number of days with headaches was reduced by 75% or more by the end of the study. On average, the number of days with migraine decreased by 11.6 per month, with monthly injections – by 12.6 per month (p<0.01). In patients who had negative experience with treatment with two or more groups of preventive therapies, the number of days with migraine was reduced by an average of 10.6 per month (p<0.01). The pain intensity according to VAS decreased from 9 to 5.7 points (p<0.001), the HIT-6 index decreased from 66 to 55 points (p<0.001). AEs occurred in 26% of cases, were transient and did not lead to discontinuation of treatment.Conclusion. The efficacy and safety of the use of fremanezumab in CM in real-world clinical practice has been demonstrated.","PeriodicalId":19252,"journal":{"name":"Neurology, neuropsychiatry, Psychosomatics","volume":"4 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140445119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-21DOI: 10.14412/2074-2711-2024-1-71-74
P. Vlasov, V. A. Karlov, I. Zhidkova, A. O. Khabibova, A. M. Azhigova, V. A. Kharkovsky
The main goal of epilepsy therapy is to improve the patient’s quality of life (QoL), which is a holistic indicator that reflects satisfaction with life in various areas. Currently existing questionnaires: QOLIE-89, QOLIE-31 and QOLIE-10 are adapted for use in Russia, but require a certain, sometimes considerable amount of time to complete them and then process. The five-point scale for assessing the QoL of epilepsy patients (SCALE 5) requires answering only one question: “Grade your general well-being on a five-point school scale at this moment?” and allows to get the necessary information in seconds, without using special forms and calculation formulas. The QoL is assessed by analogy with a Russian five-point school grading system, where 5 is an excellent grade, 4 is good etc. The resulting score serves as an immediate guideline for the doctor for further treatment of the patient: with a score of 3 (satisfactory), the cause of the reduced QoL should be identified and corrected (whether it is related to the illness, adverse events, anxiety/depression, etc.), and with scores of 2 and 1, immediate intervention is required: correction of therapy, consultation with a psychiatrist, possibly hospitalization. Here we present the results of more than 25 years of using SCALE 5. SCALE 5 is easy for patients to understand and for clinicians to use in the limited time of an outpatient appointment. The typical clinical scenarios and practical recommendations for determining the SCALE 5 score presented in the article are intended to facilitate the work of specialists in the fields of neurology, epileptology and psychiatry.
{"title":"A five-point scale for assessing the quality of life of patients with epilepsy","authors":"P. Vlasov, V. A. Karlov, I. Zhidkova, A. O. Khabibova, A. M. Azhigova, V. A. Kharkovsky","doi":"10.14412/2074-2711-2024-1-71-74","DOIUrl":"https://doi.org/10.14412/2074-2711-2024-1-71-74","url":null,"abstract":"The main goal of epilepsy therapy is to improve the patient’s quality of life (QoL), which is a holistic indicator that reflects satisfaction with life in various areas. Currently existing questionnaires: QOLIE-89, QOLIE-31 and QOLIE-10 are adapted for use in Russia, but require a certain, sometimes considerable amount of time to complete them and then process. The five-point scale for assessing the QoL of epilepsy patients (SCALE 5) requires answering only one question: “Grade your general well-being on a five-point school scale at this moment?” and allows to get the necessary information in seconds, without using special forms and calculation formulas. The QoL is assessed by analogy with a Russian five-point school grading system, where 5 is an excellent grade, 4 is good etc. The resulting score serves as an immediate guideline for the doctor for further treatment of the patient: with a score of 3 (satisfactory), the cause of the reduced QoL should be identified and corrected (whether it is related to the illness, adverse events, anxiety/depression, etc.), and with scores of 2 and 1, immediate intervention is required: correction of therapy, consultation with a psychiatrist, possibly hospitalization. Here we present the results of more than 25 years of using SCALE 5. SCALE 5 is easy for patients to understand and for clinicians to use in the limited time of an outpatient appointment. The typical clinical scenarios and practical recommendations for determining the SCALE 5 score presented in the article are intended to facilitate the work of specialists in the fields of neurology, epileptology and psychiatry.","PeriodicalId":19252,"journal":{"name":"Neurology, neuropsychiatry, Psychosomatics","volume":"4 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140442217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-21DOI: 10.14412/2074-2711-2024-1-57-64
V. Lobzin, A. Emelin, K. Kolmakova
Asthenic syndrome occurs in most chronic diseases, and doctors encounter it in outpatient appointments for both somatic and neurological pathologies. Drugs that normalize energy metabolism, have an antioxidant effect and antihypoxic properties are used to treat asthenia.Objective: to investigate the therapeutic efficacy of the drug Cytochrome C in patients with asthenia of various origin in an outpatient setting.Material and methods. The study included 147 outpatients with asthenia who received Cytochrome C 10 mg intramuscularly daily for 10 days. The assessment of the initial level of asthenia manifestations and their changes in dynamics was carried out using the MFI-20 scales, the assessment of daytime sleepiness, the assessment of fatigue (FAS), the severity of symptoms of the disease and the dynamics of the condition according to the doctor and the patient.Results. By the 10th day of therapy, there was a decrease in the severity of asthenia on the MFI-20 scale from 72.2±12.7 to 41.1±12.3 points (p<0.01), including general (by 45%), physical (by 42%) and mental (by 45%) asthenia according to the MFI-20 subscales (p<0.001), improvement in night sleep and reduction in daytime sleepiness on the Epworth scale by 65% – from 9.1±5.6 to 4.6±4.3 points (p<0.001), reduction in severity of fatigue by 29% (p<0.01). The clinically significant improvement lasted until the 30th day of observation, 3 weeks after the end of the therapy. Overall, a significant reduction in asthenia symptoms was observed in 99% of patients on day 10 of therapy and in 96% of cases on day 30.Conclusion. Cytochrome C has been shown to be very effective in patients with asthenia as it reduces all manifestations of asthenia, improves night sleep and reduces daytime sleepiness.
{"title":"Evaluation of the therapeutic efficacy of the drug Cytochrome C in the treatment of asthenia in outpatients (CITRIN study)","authors":"V. Lobzin, A. Emelin, K. Kolmakova","doi":"10.14412/2074-2711-2024-1-57-64","DOIUrl":"https://doi.org/10.14412/2074-2711-2024-1-57-64","url":null,"abstract":"Asthenic syndrome occurs in most chronic diseases, and doctors encounter it in outpatient appointments for both somatic and neurological pathologies. Drugs that normalize energy metabolism, have an antioxidant effect and antihypoxic properties are used to treat asthenia.Objective: to investigate the therapeutic efficacy of the drug Cytochrome C in patients with asthenia of various origin in an outpatient setting.Material and methods. The study included 147 outpatients with asthenia who received Cytochrome C 10 mg intramuscularly daily for 10 days. The assessment of the initial level of asthenia manifestations and their changes in dynamics was carried out using the MFI-20 scales, the assessment of daytime sleepiness, the assessment of fatigue (FAS), the severity of symptoms of the disease and the dynamics of the condition according to the doctor and the patient.Results. By the 10th day of therapy, there was a decrease in the severity of asthenia on the MFI-20 scale from 72.2±12.7 to 41.1±12.3 points (p<0.01), including general (by 45%), physical (by 42%) and mental (by 45%) asthenia according to the MFI-20 subscales (p<0.001), improvement in night sleep and reduction in daytime sleepiness on the Epworth scale by 65% – from 9.1±5.6 to 4.6±4.3 points (p<0.001), reduction in severity of fatigue by 29% (p<0.01). The clinically significant improvement lasted until the 30th day of observation, 3 weeks after the end of the therapy. Overall, a significant reduction in asthenia symptoms was observed in 99% of patients on day 10 of therapy and in 96% of cases on day 30.Conclusion. Cytochrome C has been shown to be very effective in patients with asthenia as it reduces all manifestations of asthenia, improves night sleep and reduces daytime sleepiness.","PeriodicalId":19252,"journal":{"name":"Neurology, neuropsychiatry, Psychosomatics","volume":"12 11","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140442891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-20DOI: 10.14412/2074-2711-2024-1-42-48
D. Grishina, N. Suponeva, T. Tumilovich, M. Piradov
Little attention has been paid abroad to the problem of the long-term course of multifocal motor neuropathy (MMN). In our country, catamnestic studies of MMN have not been conducted at all. However, the results of such an analysis are extremely important for understanding the course and prognosis of the disease.Objective: to analyse the clinical and neurophysiological data of patients with MMN with a disease duration of more than 5 years.Material and methods. The study included 28 patients with MMN: 9 women (32%) and 19 men (68%); the median age at admission was 50 [44; 56] years; the median disease duration was 10 [8; 13] years. Medical documentation, medical history, complaints, neurological examination results (scored on the MRC and INCAT scales) and results of electroneuromyography (ENMG) of the long nerves of the hands were analysed.Results. The median time between onset of the disease and diagnosis was 5.5 [2; 10] years. Paresis <3 points on the MRC scale was found in the extensor muscles of the hand and fingers (12/28; 43%), in the median (15/28; 53%) and ulnar (20/28; 71%) muscle groups of the hands, in the extensors (11/28; 39%) and flexors (9/28; 32%) of the feet. The median total score for the degree of disability on the INCAT scale was 3 [2; 3] for the hands and 1 [0; 2] for the legs. The comparative analysis of the severity of the neurological deficits on the MRC and INCAT scales at the onset of the disease and in the long-term catamnesis revealed no significant differences (p>0.05). An objective assessment of sensory disorders revealed no changes when testing tactile, pain and temperature sensitivity, while half of the cases (14/28; 50%) showed a disturbance of vibration sensitivity in the lower extremities. The ENMG examination was consistent with the electrophysiological criteria of the disease, one third of the patients showed significant secondary damage to the axons of the motor fibers of the hand nerves, and in half of the cases a slight impairment of the axons of the sensory fibers was registered.Conclusion. MMN is a curable disease. Unfortunately, our retrospective analysis showed that in the Russian Federation there are problems with its diagnosis and quality care of this category of patients. Late diagnosis, delayed start of treatment and non-compliance with the schedule of pathogenetic therapy lead to persistent disability of patients.
{"title":"Multifocal motor neuropathy: long-term clinical and electrophysiological features of the disease","authors":"D. Grishina, N. Suponeva, T. Tumilovich, M. Piradov","doi":"10.14412/2074-2711-2024-1-42-48","DOIUrl":"https://doi.org/10.14412/2074-2711-2024-1-42-48","url":null,"abstract":"Little attention has been paid abroad to the problem of the long-term course of multifocal motor neuropathy (MMN). In our country, catamnestic studies of MMN have not been conducted at all. However, the results of such an analysis are extremely important for understanding the course and prognosis of the disease.Objective: to analyse the clinical and neurophysiological data of patients with MMN with a disease duration of more than 5 years.Material and methods. The study included 28 patients with MMN: 9 women (32%) and 19 men (68%); the median age at admission was 50 [44; 56] years; the median disease duration was 10 [8; 13] years. Medical documentation, medical history, complaints, neurological examination results (scored on the MRC and INCAT scales) and results of electroneuromyography (ENMG) of the long nerves of the hands were analysed.Results. The median time between onset of the disease and diagnosis was 5.5 [2; 10] years. Paresis <3 points on the MRC scale was found in the extensor muscles of the hand and fingers (12/28; 43%), in the median (15/28; 53%) and ulnar (20/28; 71%) muscle groups of the hands, in the extensors (11/28; 39%) and flexors (9/28; 32%) of the feet. The median total score for the degree of disability on the INCAT scale was 3 [2; 3] for the hands and 1 [0; 2] for the legs. The comparative analysis of the severity of the neurological deficits on the MRC and INCAT scales at the onset of the disease and in the long-term catamnesis revealed no significant differences (p>0.05). An objective assessment of sensory disorders revealed no changes when testing tactile, pain and temperature sensitivity, while half of the cases (14/28; 50%) showed a disturbance of vibration sensitivity in the lower extremities. The ENMG examination was consistent with the electrophysiological criteria of the disease, one third of the patients showed significant secondary damage to the axons of the motor fibers of the hand nerves, and in half of the cases a slight impairment of the axons of the sensory fibers was registered.Conclusion. MMN is a curable disease. Unfortunately, our retrospective analysis showed that in the Russian Federation there are problems with its diagnosis and quality care of this category of patients. Late diagnosis, delayed start of treatment and non-compliance with the schedule of pathogenetic therapy lead to persistent disability of patients.","PeriodicalId":19252,"journal":{"name":"Neurology, neuropsychiatry, Psychosomatics","volume":"57 18","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140445578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：